UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study

Movement disorders, 2021-11, Vol.36 (11), p.2687-2692

2021

Volltextzugriff (PDF)

Corrigendum to “Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease” [Clin. Parkinsonism Related Dis. 9 (2023) 100223]

Clinical parkinsonism & related disorders, 2024, Vol.10, p.100250, Article 100250

2024

Volltextzugriff (PDF)

Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis

Clinical parkinsonism & related disorders, 2024-01, Vol.10, p.100256-100256, Article 100256

2024

Volltextzugriff (PDF)

Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease

Clinical parkinsonism & related disorders, 2023, Vol.9, p.100223, Article 100223

2023

Volltextzugriff (PDF)

Correction to: Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel

Neurology and therapy, 2023-10, Vol.12 (5), p.1803-1803

2023

Volltextzugriff (PDF)

Effective Treatment Strategies for Motor and Nonmotor Symptoms of Parkinson Disease

The journal of clinical psychiatry, 2020-01, Vol.81 (1)

Isaacson, Stuart H.

2020

Volltextzugriff (PDF)

Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel

Neurology and therapy, 2022-12, Vol.11 (4), p.1571-1582

2022

Volltextzugriff (PDF)

How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature

Clinical parkinsonism & related disorders, 2023-01, Vol.8, p.100174-100174, Article 100174

2023

Volltextzugriff (PDF)

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment

Clinical parkinsonism & related disorders, 2023-01, Vol.9, p.100212-100212, Article 100212

2023

Volltextzugriff (PDF)

Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier?

Clinical parkinsonism & related disorders, 2022-01, Vol.7, p.100161-100161, Article 100161

2022

Volltextzugriff (PDF)

Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions

Expert opinion on drug safety, 2022-07, Vol.21 (7), p.873-879

2022

Volltextzugriff (PDF)

Pathophysiology, Patient Burden, and Recognition of OFF Episodes of Parkinson Disease

The journal of clinical psychiatry, 2020-10, Vol.81 (6)

2020

Volltextzugriff (PDF)

Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson’s disease experiencing OFF episodes: A modified Delphi panel

Clinical parkinsonism & related disorders, 2024-01, Vol.11, p.100264, Article 100264

2024

Volltextzugriff (PDF)

Clinical implications of gastric complications on levodopa treatment in Parkinson's disease

Parkinsonism & related disorders, 2020-07, Vol.76, p.63-71

2020

Volltextzugriff (PDF)

Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study

Clinical parkinsonism & related disorders, 2022-01, Vol.6, p.100142-100142, Article 100142

2022

Volltextzugriff (PDF)

Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial

Clinical parkinsonism & related disorders, 2023-01, Vol.8, p.100181-100181, Article 100181

2023

Volltextzugriff (PDF)

Importance of time to ON versus wearing OFF in total daily OFF time experienced by patients with Parkinson's disease

Parkinsonism & related disorders, 2023-09, Vol.114, p.105495-105495, Article 105495

2023

Volltextzugriff (PDF)

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial

JAMA neurology, 2017-08, Vol.74 (8), p.941

2017

Volltextzugriff (PDF)

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial

Lancet neurology, 2019-02, Vol.18 (2), p.145-154

2019

Volltextzugriff (PDF)

Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial

JAMA neurology, 2020-04, Vol.77 (4), p.461

2020

Volltextzugriff (PDF)

AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions

Clinical parkinsonism & related disorders, 2021-01, Vol.5, p.100115-100115, Article 100115

2021

Volltextzugriff (PDF)

Impact of DaTscan Imaging on Clinical Decision Making in Clinically Uncertain Parkinson's Disease

Journal of Parkinson's disease, 2021-01, Vol.11 (2), p.885-889

2021

Volltextzugriff (PDF)

Clinical benefit of transcutaneous afferent patterned stimulation (TAPS) in essential tremor patients with high unmet need: a secondary analysis of TAPS studies

Expert review of medical devices, 2023-12, Vol.20 (12), p.1211-1218

2023

Volltextzugriff (PDF)

Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study

Journal of neurology, 2024-06, Vol.271 (6), p.3554-3570

2024

Volltextzugriff (PDF)

1 – 25 von 122

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(117)
Mit Volltextzugriff
(84)

Publikationsform

Sprache

Englisch
(122)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study

Corrigendum to “Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease” [Clin. Parkinsonism Related Dis. 9 (2023) 100223]

Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis

Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson’s disease

Correction to: Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel

Effective Treatment Strategies for Motor and Nonmotor Symptoms of Parkinson Disease

Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel

How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment

Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier?

Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions

Pathophysiology, Patient Burden, and Recognition of OFF Episodes of Parkinson Disease

Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson’s disease experiencing OFF episodes: A modified Delphi panel

Clinical implications of gastric complications on levodopa treatment in Parkinson's disease

Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study

Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial

LIPAD (LRRK2/Luebeck International Parkinson's Disease) Study Protocol: Deep Phenotyping of an International Genetic Cohort

Importance of time to ON versus wearing OFF in total daily OFF time experienced by patients with Parkinson's disease

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial

Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial

AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions

Impact of DaTscan Imaging on Clinical Decision Making in Clinically Uncertain Parkinson's Disease

Clinical benefit of transcutaneous afferent patterned stimulation (TAPS) in essential tremor patients with high unmet need: a secondary analysis of TAPS studies

Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study

Suchergebnisse filtern